Bulevirtide, the first targeted therapy for chronic hepatitis D: what we know up to now

Future Virology · Published 2025-11-02 · DOI 10.1080/17460794.2025.2581498

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1080/17460794.2025.2581498

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Emerging evidence of viral involvement in testicular and penile carcinogenesis · Future Virology · 2026 · Same journal
• Quantitative analysis of Epstein–Barr virus in upper respiratory tract samples of hospitalized patients with COVID-19 · Future Virology · 2026 · Same journal
• Exosome-based strategies for COVID-19: a comprehensive review of diagnostic and therapeutic applications · Future Virology · 2026 · Same journal
• Incidentally detected acute hepatitis B and concomitant acute acalculous cholecystitis: a rare case report · Future Virology · 2026 · Same journal
• New antiviral peptides inhibit in vitro infection of SARS-CoV-2 · Future Virology · 2025 · Same journal
• Photodynamic therapy at low power laser enhances the oncolytic Newcastle disease virus in killing breast cancer cells · Future Virology · 2026 · Same journal
• Clinical markers dysregulation during HTLV-1 infection and associated diseases · Future Virology · 2026 · Same journal
• The Janus face of statins in viral infections: integrating findings from preclinical and clinical studies · Future Virology · 2026 · Same journal
• Advancements in rabies immunization: transformations from early trials to cutting-edge technologies · Future Virology · 2026 · Same journal
• When defense backfires: inflammatory determinants of RSV-induced disease severity · Future Virology · 2026 · Same journal